ArticleBiomedicines2022

Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer.

Chih-Cheng Tsao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.